Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects
Mohammad Belal Omari,1 Shafiqullah Naseri,2 Abdul Jalil Hassan3 1Department of Endocrinology, Hematology and Rheumatology, Ali Abad Teaching Hospital, Kabul University of Medical Sciences “Abu Ali Ibn Sina”, Kabul, Afghanistan; 2Cardio-Pulmonary Department, Ali Abad Teaching Hospital, Kabul Universi...
Main Authors: | Omari MB, Naseri S, Hassan AJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-03-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/drug-safety-evaluation-of-sodium-glucose-cotransporter-2-inhibitors-in-peer-reviewed-fulltext-article-DMSO |
Similar Items
-
Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01) -
Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
by: Miho Murashima, et al.
Published: (2022-04-01) -
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01) -
Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01) -
Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)